Press Release August 19, 2020

Tango Therapeutics Announces $50 Million Equity Financing

The Life Sciences team advised Tango Therapeutics on its $50 million equity financing.

Tango is a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies. The company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.

The financing was led by Casdin Capital and included existing investors Boxer Capital of the Tavistock Group and Cormorant Asset Management as well as new investor Gilead Sciences. The company will use the funding to initiate clinical studies of its lead program in the next 18 months and drive progress for other wholly owned programs in late-stage drug discovery.

The Goodwin team was led by Gabriela Morales-Rivera and Bill Collins, and included Mitchell Bloom and Katie Hand.

For more details, read the press release and articles in Pitchbook, Endpoints, FierceBiotech, and Xconomy.